About LUDC

Our vision at LUDC is to improve patient stratification and to undertake innovative translational studies that lead to better prevention and management of diabetes and its complications through precision diabetes medicine.

At LUDC, more than 300 people work in a vibrant research environment consisting of more than 30 research groups. Our scientists work within the Lund University strategic research area EXODIAB (Excellence of Diabetes Research in Sweden). EXODIAB is a joint strategic diabetes research initiative at Lund University and Uppsala University.

Within the framework of EXODIAB, our scientists look for new treatments and drugs to prevent, delay, or cure diabetes. The research teams also work towards developing personalised care and treatment for patients with diabetes. Various fields of research are integrated within clinical studies and population studies (epidemiology), and platforms for collaboration between academia and industry are created.

Translational research

LUDC is dedicated to translational research, and the centre seeks to translate scientific discoveries into practice. To this end, LUDC-Industrial Research Centre (LUDC-IRC) was formed in 2017. LUDC-IRC is funded by a major grant from the Swedish Foundation for Strategic Research (SSF) and is today made up of eight partners from the public and private sectors.

An important part of industrial research at LUDC is to identify and validate biomarkers that can accurately predict disease progression and treatment responses. LUDC-IRC works towards a better understanding of mechanisms and pathways behind diabetes progression and treatment responses to enable the right prevention and treatment for the right patients at the right time.